The tweet was deleted by the author.
But we saved everything 🙂.
Urogen Pharma has named Mark, an internationally recognized expert in urothelial cancer, to help advance its work in urologic oncology.
With decades of clinical and academic leadership, Mark is expected to accelerate research efforts as the company seeks to deliver new progress for patients. Urogen Pharma emphasized Mark's commitment to research as a key driver behind their shared ambition to improve outcomes in the field. Details on specific initiatives and research programs are available on the company’s website.
Urogen Pharma recently attended the SES AUA event in Puerto Rico to engage clinicians and encourage innovation in urologic care. The company continues to focus on collaboration within the clinical community. Its efforts remain centered on developing advances in urologic oncology.